Safety and immunogenicity of the LC16m8 vaccine against mpox during outbreak deployment in Colombia: a hybrid, multicentre, open-label, randomised controlled trial and observational cohort study

BACKGROUND: LC16m8 is a live-attenuated, replication-competent vaccinia vaccine, but clinical evidence on its efficacy against mpox remains limited. We assessed its efficacy and safety in adults at increased risk of mpox in Colombia. METHODS: We conducted a hybrid study comprising a multicentre, open-label, randomised delayed-vaccination trial and an observational cohort at three centres in Bogotá. Adults aged 18-50 years were randomised 1:1 using stratified permuted blocks to receive one percutaneous dose of LC16m8 at enrolment (Day 0) or on Day 42. The primary outcome was PCR-confirmed mpox during the arm-specific efficacy-assessment windows, analysed in the per-protocol efficacy population; no efficacy outcomes were imputed. Safety outcomes were assessed through Day 180. CLINICALTRIALS: govNCT06223919; retrospectively registered; trial closed to recruitment. FINDINGS: Between December 16, 2023, and January 6, 2024, 208 participants were enrolled and 204 randomised (104 immediate; 100 delayed); 203 were male and one female. The trial randomised 204 of 8686 planned participants. No PCR-confirmed mpox cases occurred in the primary per-protocol efficacy analysis (0/97 immediate vs 0/69 delayed); therefore, the prespecified hazard ratio, 95% CI, p value, and vaccine efficacy were not estimable. Through Day 180, at least one adverse event was reported by 96/98 (98·0%) participants in the immediate-vaccination group and 68/69 (98·6%) in the delayed-vaccination group. One serious adverse event occurred in each group; both were unrelated to vaccination and resolved. No deaths or adverse-event-related study discontinuations occurred. INTERPRETATION: Substantial under-recruitment and the absence of primary outcome events precluded estimation of LC16m8 efficacy. The randomised safety findings were limited by the small sample size. FUNDING: Japan Agency for Medical Research and Development (AMED; JP22fk0108503h0001); Ministry of Health and Social Protection of Colombia; Universidad Nacional de Colombia; National Institute of Health of Colombia.

Authors

Institutions

Publication Details

Journal
EBioMedicine
Published
2026-11-13
DOI
https://doi.org/10.1016/j.ebiom.2026.106549
Primary Topic
Poxvirus research and outbreaks
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Safety and immunogenicity of the LC16m8 vaccine against mpox during outbreak deployment in Colombia: a hybrid, multicentre, open-label, randomised controlled trial and observational cohort study

Akira Ainai, Sandra Valderrama, Sandra Susana Novoa-Herrán, Hernando Gaitán‐Duarte et al.
4 links
EBioMedicine
Poxvirus research and outbreaks
article

Safety and immunogenicity of the LC16m8 vaccine against mpox during outbreak deployment in Colombia: a hybrid, multicentre, open-label, randomised controlled trial and observational cohort study

Akira Ainai, Sandra Valderrama, Sandra Susana Novoa-Herrán, Hernando Gaitán‐Duarte, Naoki Tomotsugu, Sohtaro Mine, Laura Cristina Nócua-Báez, Diego Alejandro Álvarez-Díaz, Yasukata Ohashi, Alejandra M. Muñoz-Suarez, Milagros Virhuez-Mendoza, Tadaki Suzuki, Mugen Ujiie, Mieko Hamana, Norio Ohmagari, Otto Sussman, Carlos Álvarez, Shiori Ueno, Carlos Gómez, Jorge Alberto Cortés, Johana Hernández, Gloria Mercedes Puerto, Maria Jose Amaya Mahecha, María Del Mar Bautista-Gonzalez, Ken Maeda, Jaime Castellanos, Valentina Guevara-Prieto, Claudia Marcela Castro-Osorio, Luz Mery González
article en

Abstract

BACKGROUND: LC16m8 is a live-attenuated, replication-competent vaccinia vaccine, but clinical evidence on its efficacy against mpox remains limited. We assessed its efficacy and safety in adults at increased risk of mpox in Colombia. METHODS: We conducted a hybrid study comprising a multicentre, open-label, randomised delayed-vaccination trial and an observational cohort at three centres in Bogotá. Adults aged 18-50 years were randomised 1:1 using stratified permuted blocks to receive one percutaneous dose of LC16m8 at enrolment (Day 0) or on Day 42. The primary outcome was PCR-confirmed mpox during the arm-specific efficacy-assessment windows, analysed in the per-protocol efficacy population; no efficacy outcomes were imputed. Safety outcomes were assessed through Day 180. CLINICALTRIALS: govNCT06223919; retrospectively registered; trial closed to recruitment. FINDINGS: Between December 16, 2023, and January 6, 2024, 208 participants were enrolled and 204 randomised (104 immediate; 100 delayed); 203 were male and one female. The trial randomised 204 of 8686 planned participants. No PCR-confirmed mpox cases occurred in the primary per-protocol efficacy analysis (0/97 immediate vs 0/69 delayed); therefore, the prespecified hazard ratio, 95% CI, p value, and vaccine efficacy were not estimable. Through Day 180, at least one adverse event was reported by 96/98 (98·0%) participants in the immediate-vaccination group and 68/69 (98·6%) in the delayed-vaccination group. One serious adverse event occurred in each group; both were unrelated to vaccination and resolved. No deaths or adverse-event-related study discontinuations occurred. INTERPRETATION: Substantial under-recruitment and the absence of primary outcome events precluded estimation of LC16m8 efficacy. The randomised safety findings were limited by the small sample size. FUNDING: Japan Agency for Medical Research and Development (AMED; JP22fk0108503h0001); Ministry of Health and Social Protection of Colombia; Universidad Nacional de Colombia; National Institute of Health of Colombia.

EBioMedicineVol. 134
Pontificia Universidad Javeriana (CO), Universidad Nacional de Colombia (CO), Instituto Nacional de Salud (CO), Hospital Universitario San Ignacio (CO), Fundación Universitaria Sanitas (CO), Japan Institute for Health Security (JP)
Instituto Nacional de Salud, Japan Agency for Medical Research and Development, Universidad Nacional de Colombia, Ministerio de Salud y Protección Social
Good health and well-being
Poxvirus research and outbreaks
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon